Durvalumab made available for NSCLC for routine use via NHS England

The National Institute of Health and Care Excellence (NICE, UK) has recommended Imfinzi (durvalumab) as a monotherapy option for locally advanced Stage III NSCLC via the NHS in England. The drug, produced by AstraZeneca (London, UK), was previously made available via the Cancer Drug Fund in May 2019. The latest recommendation from NICE comes as a result of the data collected between May 2019 to present, as well as encouraging data from the PACIFIC Phase III trial. A collective review of 5 years of data highlighted that the median progression-free survival was just over 2 years for people with locally...